CRITICAL ANALYSIS ON TIME-TO-REIMBURSEMENT OF RARE DISEASE DRUGS: THE ITALIAN CASE (AIFA COMMISSIONS 2018-2022)

被引：0
|
作者：
Raimondo, P. [1 ]
Giorgio, D. [1 ]
Ravasio, R. [1 ]
Leonetti, E. [1 ]
Luccini, F. [1 ]
机构：
[1] MA Provider Srl, Milan, MI, Italy
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR24
引用
收藏
页码：S236 / S236
页数：1
相关论文
共 2 条
  • [1] Impact of reimbursement reform on Finnish occupational health service trends in 2018-2022: an interrupted time series analysis
    Oksanen, Katri
    Viljamaa, Mervi
    Reho, Tiia
    Korhonen, Mikko
    Sauni, Riitta
    BMJ OPEN, 2025, 15 (03):
  • [2] Impacts of the COVID-19 pandemic on the availability and retail price of unregulated drugs in Vancouver, Canada: An interrupted time-series analysis, 2018-2022
    Swaich, Anmol
    Ignatieff, Delaney
    Milloy, M. J.
    Choi, JinCheol
    Kerr, Thomas
    Hayashi, Kanna
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2024, 134
1